Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    85,999.95
    -2,090.82 (-2.37%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Today’s Research Reports on Emblem Corp., Cronos Group Inc., Calyx Bio-Ventures Inc. and Theralase Technologies Inc.

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / January 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Emblem Corp.
https://rdinvesting.com/news/?ticker=EMC.V

Cronos Group Inc.
https://rdinvesting.com/news/?ticker=MJN.V

Calyx Bio-Ventures Inc.
https://rdinvesting.com/news/?ticker=CYX.V

Theralase Technologies Inc.
https://rdinvesting.com/news/?ticker=TLT.V

ADVERTISEMENT

Emblem Corp.'s stock edged 0.81% lower Wednesday, to close the day at $2.45. The stock recorded a trading volume of 989,873 shares, which was below its three months average volume of 1,170,873 shares. In the last year, Emblem Corp.'s shares have traded in a range of 1.47 - 26.32. The share price has gained 66.67% from its 52-week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.90 is below its 200-day moving average of $1.96. Shares of Emblem have gained approximately 7.46 percent year-to-date.

Access RDI's Emblem Corp. Research Report at:
https://rdinvesting.com/news/?ticker=EMC.V

On Wednesday, shares of Cronos Group Inc. recorded a trading volume of 1,209,723 shares, which was above the three months average volume of 1,137,526 shares. The stock ended the day 2.34% lower at 13.36. The share price has gained 745.57% from its 52-week low with a 52-week trading range of 1.58 - 14.83.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $6.20 is greater than its 200-day moving average of $3.46. Shares of the company are trading at a Price to Earnings ratio of 1,214.55. Shares of Cronos Group have gained approximately 37.17 percent year-to-date.

Access RDI's Cronos Group Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MJN.V

Calyx Bio-Ventures stock moved 8.93% lower Wednesday, to close the day at $0.26. The stock recorded a trading volume of 1,714,057 shares, which was below its three months average volume of 3,162,044 shares. In the last year, Calyx Bio-Ventures shares have traded in a range of 0.05 - 0.42. The share price has gained 466.67% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.27 is greater than its 200-day moving average of $0.13. Shares of Calyx Bio-Ventures have fallen approximately 10.53 percent year-to-date.

Access RDI's Calyx Bio-Ventures Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CYX.V

On Wednesday, shares of Theralase Technologies Inc. recorded a trading volume of 313,002 shares, which was below the three months average volume of 579,257 shares. The stock ended the day 4.44% lower at 0.21. The stock is currently trading 60.91% below its 52-week high with a 52-week trading range of 0.19 - 0.55.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.26 is below its 200-day moving average of $0.39. Shares of Theralase Technologies have fallen approximately 12.24 percent year-to-date.

Access RDI's Theralase Technologies Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TLT.V

Our Actionable Research on Emblem Corp. (TSXV:EMC.V), Cronos Group Inc. (TSXV:MJN.V), Calyx Bio-Ventures Inc. (TSXV:CYX.V) and Theralase Technologies Inc. (TSXV:TLT.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com